Do analysts rate ADIL or GLMD?

Adial Pharmaceuticals currently has a consensus price target of $15.63, suggesting a potential upside of 210.57%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Adial Pharmaceuticals is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ADIL or GLMD?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$14.73 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is ADIL or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -203.87% -512.41% Galmed Pharmaceuticals N/A -73.68% -60.88%

Do analysts prefer CYCN or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate GLMD or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 775.66%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better valuation and earnings, GLMD or CTXR?

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$1.67 N/A

Is GLMD or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -73.68% -60.88% Citius Pharmaceuticals N/A -59.57% -34.47%

Does the media favor GLMD or CTXR?

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 2 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.94 beat Galmed Pharmaceuticals' score of 0.71 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SCNX or GLMD?

Scienture currently has a consensus price target of $1.50, suggesting a potential upside of 354.55%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNX or GLMD more profitable?

Scienture's return on equity of -53.51% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Galmed Pharmaceuticals N/A -73.68% -60.88%

Does the media prefer SCNX or GLMD?

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Scienture. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 3 mentions for Scienture. Scienture's average media sentiment score of 0.72 beat Galmed Pharmaceuticals' score of 0.71 indicating that Scienture is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scienture 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GLMD or MBRX?

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 289.61%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger earnings & valuation, GLMD or MBRX?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is GLMD or MBRX more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -73.68% -60.88% Moleculin Biotech N/A -143.51% -24.53%

Does the media favor GLMD or MBRX?

In the previous week, Moleculin Biotech had 2 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 6 mentions for Moleculin Biotech and 4 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.71 beat Moleculin Biotech's score of 0.39 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Galmed Pharmaceuticals (GLMD) Competitors

$4.59 -0.04 (-0.86%)

Closing price 09/9/2026

Extended Trading

$4.59 0.00 (0.00%)

As of 09/9/2026 07:56 PM Eastern

Compare

GLMD vs. ADIL, CYCN, CTXR, SCNX, and MBRX

Should you buy Galmed Pharmaceuticals stock or one of its competitors? Galmed Pharmaceuticals's main competitors and comparable companies include Adial Pharmaceuticals (ADIL), Cyclerion Therapeutics (CYCN), Citius Pharmaceuticals (CTXR), Scienture (SCNX), and Moleculin Biotech (MBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Galmed Pharmaceuticals compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.89 beat Galmed Pharmaceuticals' score of 0.71 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
Galmed Pharmaceuticals	Positive

Adial Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Galmed Pharmaceuticals' return on equity of -73.68% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 8.0% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Adial Pharmaceuticals currently has a consensus price target of $15.63, suggesting a potential upside of 210.57%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Adial Pharmaceuticals is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Adial Pharmaceuticals beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ:CYCN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 2 mentions for Cyclerion Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.71 beat Cyclerion Therapeutics' score of 0.58 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclerion Therapeutics	Positive
Galmed Pharmaceuticals	Positive

Cyclerion Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Galmed Pharmaceuticals' return on equity of -73.68% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Cyclerion Therapeutics has higher revenue and earnings than Galmed Pharmaceuticals. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

Summary

Galmed Pharmaceuticals beats Cyclerion Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Citius Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Citius Pharmaceuticals' return on equity of -59.57% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%
Citius Pharmaceuticals	N/A	-59.57%	-34.47%

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galmed Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 2 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.94 beat Galmed Pharmaceuticals' score of 0.71 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 775.66%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Citius Pharmaceuticals beats Galmed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Scienture?

Scienture (NASDAQ:SCNX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Scienture. MarketBeat recorded 4 mentions for Galmed Pharmaceuticals and 3 mentions for Scienture. Scienture's average media sentiment score of 0.72 beat Galmed Pharmaceuticals' score of 0.71 indicating that Scienture is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scienture	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galmed Pharmaceuticals has lower revenue, but higher earnings than Scienture. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	31.51	-$41.51M	-$2.10	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

5.7% of Scienture shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scienture currently has a consensus price target of $1.50, suggesting a potential upside of 354.55%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scienture has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Scienture's return on equity of -53.51% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Summary

Scienture beats Galmed Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Moleculin Biotech?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Galmed Pharmaceuticals' return on equity of -73.68% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%
Moleculin Biotech	N/A	-143.51%	-24.53%

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 289.61%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Moleculin Biotech had 2 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 6 mentions for Moleculin Biotech and 4 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.71 beat Moleculin Biotech's score of 0.39 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Galmed Pharmaceuticals has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

Summary

Moleculin Biotech beats Galmed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.78M	$12.42B	$7.21B	$15.01B
Dividend Yield	N/A	2.63%	2.57%	12.21%
P/E Ratio	-0.30	789.61	272.86	25.31
Price / Sales	N/A	951.39	706.15	112.46
Price / Cash	N/A	89.50	77.71	51.48
Price / Book	0.20	10.39	10.44	6.18
Net Income	-$10.31M	$2.83B	$3.49B	$357.96M
7 Day Performance	-0.86%	-1.54%	-0.76%	-0.56%
1 Month Performance	9.91%	0.78%	-0.38%	-3.62%
1 Year Performance	-61.23%	3.89%	18.93%	6.05%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.1259 of 5 stars	$4.59 -0.9%	N/A	-60.7%	$4.78M	N/A	N/A	20	Positive News Short Interest Decrease Gap Up High Trading Volume
ADIL Adial Pharmaceuticals	3.1005 of 5 stars	$6.25 -6.0%	$15.63 +150.0%	-42.9%	$16.39M	N/A	N/A	20	Positive News
CYCN Cyclerion Therapeutics	1.109 of 5 stars	$3.49 +3.9%	N/A	-78.9%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
CTXR Citius Pharmaceuticals	2.4573 of 5 stars	$0.59 -1.2%	$5.00 +743.2%	-50.9%	$16.28M	N/A	N/A	20
SCNX Scienture	3.0256 of 5 stars	$0.37 +1.5%	$1.50 +306.5%	-66.3%	$15.19M	$430K	N/A	N/A	Short Interest Decrease Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. ADIL, CYCN, CTXR, SCNX, and MBRX

How does Galmed Pharmaceuticals compare to Adial Pharmaceuticals?

Summary

How does Galmed Pharmaceuticals compare to Cyclerion Therapeutics?

Summary

How does Galmed Pharmaceuticals compare to Citius Pharmaceuticals?

Summary

How does Galmed Pharmaceuticals compare to Scienture?

Summary

How does Galmed Pharmaceuticals compare to Moleculin Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. ADIL, CYCN, CTXR, SCNX, and MBRX

How does Galmed Pharmaceuticals compare to Adial Pharmaceuticals?

Which has preferable earnings and valuation, ADIL or GLMD?

Does the media prefer ADIL or GLMD?

Which has more volatility and risk, ADIL or GLMD?

Is ADIL or GLMD more profitable?

Do institutionals and insiders have more ownership in ADIL or GLMD?

Do analysts rate ADIL or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Cyclerion Therapeutics?

Do institutionals & insiders have more ownership in CYCN or GLMD?

Do analysts prefer CYCN or GLMD?

Does the media prefer CYCN or GLMD?

Which has more risk and volatility, CYCN or GLMD?

Is CYCN or GLMD more profitable?

Which has preferable valuation & earnings, CYCN or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Citius Pharmaceuticals?

Is GLMD or CTXR more profitable?

Do institutionals and insiders believe in GLMD or CTXR?

Which has more risk and volatility, GLMD or CTXR?

Which has better valuation and earnings, GLMD or CTXR?

Does the media favor GLMD or CTXR?

Do analysts rate GLMD or CTXR?

Summary

How does Galmed Pharmaceuticals compare to Scienture?

Does the media prefer SCNX or GLMD?

Which has stronger earnings & valuation, SCNX or GLMD?

Do institutionals & insiders have more ownership in SCNX or GLMD?

Do analysts recommend SCNX or GLMD?

Which has more volatility and risk, SCNX or GLMD?

Is SCNX or GLMD more profitable?

Summary

How does Galmed Pharmaceuticals compare to Moleculin Biotech?

Is GLMD or MBRX more profitable?

Do analysts prefer GLMD or MBRX?

Does the media favor GLMD or MBRX?

Do institutionals and insiders have more ownership in GLMD or MBRX?

Which has more volatility & risk, GLMD or MBRX?

Which has stronger earnings & valuation, GLMD or MBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools